Celldex Therapeutics (CLDX) Earnings Analysis

Celldex Therapeutics (CLDX) next reports earnings on 2026-08-06, consensus EPS -1.04 USD. Last quarter (2026-05-07) it missed with EPS -1.18 USD vs -1.1472 USD est (-2.9%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -8.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CLDX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-1.04 USD
Revenue estimate0.00B

CLDX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-1.18 USD-1.1472 USD-2.9%Miss
2026-02-25-1.22 USD-1 USD-22%Miss
2025-11-10-1.01 USD-0.88 USD-14.8%Miss
2025-08-07-0.85 USD-0.86 USD+1.2%Beat
2025-05-08-0.81 USD-0.75 USD-8%Miss
2025-02-27-0.71 USD-0.73 USD+2.7%Beat
2024-08-08-0.54 USD-0.59 USD+8.5%Beat

Beat rate: 3/7 (43%) over reported quarters with consensus data.

CLDX valuation and analyst view

Trailing P/E-8.14
Trailing EPS-4.26177 USD
Price / book5.07
Dividend yield0.00%
Market cap2.26B
Analyst consensusBuy (16 buy / 3 hold / 0 sell)
Avg price target58.44 USD

Related research pages

Frequently asked questions

When is Celldex Therapeutics (CLDX)'s next earnings date?

Celldex Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.04 USD and revenue estimate of 0.00B.

Did CLDX beat earnings last quarter?

In its 2026-05-07 report, CLDX posted EPS of -1.18 USD versus a -1.1472 USD estimate — a miss of 2.9%.

What is CLDX's earnings track record?

Over the last 7 reported quarters with consensus data, CLDX beat estimates 3 times (43%).

What is CLDX's current P/E ratio and EPS?

CLDX trades at a trailing P/E of -8.14 on trailing EPS of -4.2617702731124 USD.

What do analysts rate CLDX?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 58.44 USD.